Background: Burkholderia pseudomallei, an intracellular gram-negative bacterium, is the causative agent of melioidosis. It is a highly infectious disease that usually involves the lungs of humans as well as animals endemic in South-East Asia and Northern Australia. At present, we do not have any vaccine or treatment scheme at our disposal which is absolutely effective against this disease. There have been few advances in the development of vaccines against intracellular bacterial pathogens, making vaccine development against intracellular pathogen a more challenging arena. So, we opted for in-silico methods of drug designing intending to combat B. pseudomallei.Results: The whole proteome of B. pseudomallei was analyzed for determining immunogenic proteins. Combining B-cell and T-cell epitope prediction studies, the sequence ETAAADALY was considered as the most potential epitope for both T and B cells, followed by molecular docking against an MHC (major histocompatibility complex) Class I molecule, HLA-A*26:01 (human leukocyte antigens encoded by the HLA-A locus). Apart from epitope prediction, hydrogen bond study and target site analysis were carried out which concludes that ARG 237, ALA 234, ARG 236, ARG 262, GLN 226, ASP229, VAL 230, VAL 239, GLY 258, LEU259, ASN 225, and ILE 254 consist the best active site of the protein molecule. The study of the bacterial antigenic protein model's secondary structure and stereochemical properties provided an insight into the protein's stability as our epitope of choice. The post docking interactions were further subjected to molecular dynamics simulation and the system biology approach for validation. Conclusion: The goal of our endeavor is to delve into an integrative Immunoinformatics study combined with the system biology logistics of B. pseudomallei to detect potential vaccine candidates against this pathogen as well as providing a depiction of the bacterial immunome that could be insightful for vaccine generation in the future.